Swiss TPH
Swiss TPH
Location: Basel - North West Switzerland
Category: Health
The Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institute in global health with a particular focus on low- and middle-income countries. Associated with the University of Basel, Swiss TPH combines research, education and services at local, national and international level. 950 staff and students from 95 nations work at Swiss TPH focusing on climate change, environment and health, infectious and non-communicable diseases, societal and cultural context, and health systems and policies.
Swiss TPH is a public-law institution and currently receives 22% of its annual income of around 105 million Swiss francs from the cantons of Basel-Stadt and Basel-Landschaft, the federal government and the University of Basel. The remaining 78% is raised competitively from funding agencies, foundations and clients.
Since January 2022, the institute has its headquarters in Allschwil in the Canton of Basel-Landschaft. The Centre for Tropical and Travel Medicine has been located in Basel-Stadt since January 2024.
news.myScience
Promising Malaria Vaccine Candidate Boosts Immunity in Adults Living in Endemic Regions
SUM-101, a new malaria vaccine candidate has shown to be safe and to trigger strong immune responses in adults living in a malaria-endemic region of Tanzania. The study, conducted by researchers from the Ifakara Health Institute (IHI), the Swiss Tropical and Public Health Institute (Swiss TPH) and Sumaya Biotech GmbH & Co. KG (Sumaya Biotech), represents an important step towards developing next-generation vaccines to complement existing malaria prevention tools.
From Research to Impact: Tackling Female Genital Schistosomiasis
Female Genital Schistosomiasis (FGS), a neglected tropical disease caused by parasitic infection, affects an estimated 50 million women and girls, with another 150 million at risk. Despite its devastating impact including infertility, pregnancy complications, increased HIV risk, and social exclusion, FGS remains largely invisible in medical curricula, public health programmes, and global health priorities. Swiss TPH is part of the new African-European initiative WINGS-4-FGS, aimed at improving care for women suffering from this disease.
New Drug Candidate to Tackle Resistant Malaria Strains
Bacterial pathogens becoming resistant to antibiotics is well known. But resistance is also emerging among parasites - including those that cause malaria. As existing medicines lose effectiveness, researchers from Swiss TPH and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and partners have developed a new drug candidate that can kill malaria parasites even when standard treatments fail. The findings were published in Angewandte Chemie.
